{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:19:56Z","timestamp":1783153196219,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU- S114008"],"award-info":[{"award-number":["KMU- S114008"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euros.2026.03.020","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:03:50Z","timestamp":1776816230000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment Persistence and Adherence with Overactive Bladder Medications in Taiwan: A Retrospective Database Analysis"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2050-9703","authenticated-orcid":false,"given":"Shiau-Han","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-3957","authenticated-orcid":false,"given":"Chung-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid Abdul","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.03.020_b0005","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.03.020_b0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study","volume":"11","author":"Chuang","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euros.2026.03.020_b0015","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0025","first-page":"406","article-title":"Health resource utilization and cost for patients with incontinent overactive bladder treated with anticholinergics","volume":"22","author":"Yehoshua","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.euros.2026.03.020_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0050","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5489\/cuaj.3098","article-title":"Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada","volume":"9","author":"Wagg","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euros.2026.03.020_b0055","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/nau.24776","article-title":"Mirabegron has longer treatment persistence than antimuscarinics: real-world data from a Korean national cohort database","volume":"40","author":"Lee","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euros.2026.03.020_b0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12894-018-0390-z","article-title":"A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain","volume":"18","author":"Nazir","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40266-021-00884-0","article-title":"Anticholinergic burden and associated healthcare resource utilization in older adults with overactive bladder","volume":"38","author":"Jaggi","year":"2021","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euros.2026.03.020_b0070","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/iju.13758","article-title":"Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0075","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/nau.25040","article-title":"Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population","volume":"41","author":"Johnson","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euros.2026.03.020_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.euros.2026.03.020_b0085","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1136\/injuryprev-2019-043286","article-title":"The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017","volume":"26(Suppl. 1)","author":"James","year":"2020","journal-title":"Inj Prev"},{"key":"10.1016\/j.euros.2026.03.020_b0090","unstructured":"Harding CK, Lapitan MC, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. Limited Update; 2023, https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-neurogenic-Female-LUTS-2024.pdf."},{"key":"10.1016\/j.euros.2026.03.020_b0095","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2018062","article-title":"Data resource profile: the National Health Insurance Research Database (NHIRD)","volume":"40","author":"Lin","year":"2018","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.euros.2026.03.020_b0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's National Health Insurance Research Database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.euros.2026.03.020_b0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern MedAnn Intern Med"},{"key":"10.1016\/j.euros.2026.03.020_b0110","first-page":"e25","article-title":"Persistence with mirabegron versus tolterodine in patients with overactive bladder","volume":"8","author":"Nitti","year":"2016","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.euros.2026.03.020_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.euros.2026.03.020_b0120","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.03.020_b0125","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/luts.12382","article-title":"Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study","volume":"13","author":"Carlson","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euros.2026.03.020_b0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-021-01020-x","article-title":"Overactive bladder prescribing considerations: the role of polypharmacy, anticholinergic burden, and CYP2D6 drug\u2012drug interactions","volume":"41","author":"Rutman","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.euros.2026.03.020_b0135","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2011.10436.x","article-title":"Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting","volume":"109","author":"Asche","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2026.03.020_b0140","first-page":"421","article-title":"The prevalence of cardiovascular risk factors in male patients who have lower urinary tract symptoms","volume":"13","author":"Ng","year":"2007","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.euros.2026.03.020_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.urology.2020.10.033","article-title":"The effect of cardiovascular morbidity on clinical responsiveness to anticholinergics in postmenopausal women with urge urinary incontinence","volume":"147","author":"Selvi","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.euros.2026.03.020_b0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.03.020_b0155","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.03.020_b0160","unstructured":"Cornu JN, Gacci M, Hashim H, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). Update 2024, https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-Neurogenic-Male-LUTS-2024.pdf."},{"key":"10.1016\/j.euros.2026.03.020_b0165","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","article-title":"The association between overactive bladder and falls and fractures: a systematic review","volume":"35","author":"Szabo","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.euros.2026.03.020_b0170","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euros.2026.03.020_b0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euros.2026.03.020_b0180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.24827","article-title":"The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications","volume":"41","author":"Welk","year":"2022","journal-title":"Neurourol Urodyn"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:59:53Z","timestamp":1783151993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"alternative-id":["S2666168326000765"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.03.020","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Persistence and Adherence with Overactive Bladder Medications in Taiwan: A Retrospective Database Analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}